Phase III Medical Company Spectral Medical Inc. (TSX: EDT, OTC: EDTXF, Forum) released its Q1 2019 results on Thursday, with cash on hand of $4,613,000 compared to $4,368,000 as of December 31, 2018. Operating costs for the quarter ending March 31, 2019 were $1,540,000 compared to $1,877,000 for the same period in 2018. Revenue also decreased from $547,000 compared to $1,163,000 from Q4 due to the expiry of certain patients, but the Company notes that this was partially offset by a technology transfer agreement.
For more on these results, click here.
Spectral Medical Inc. was also covered by Stockhouse Editorial this week in a new feature-lengtharticle, looking at the Company’s efforts to develop the first treatment for patients with septic shock guided by a companion diagnostic.
FULL DISCLOSURE: Spectral Medical Inc. is a client of Stockhouse Publishing.